SynthesisAllergy2025
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence.
Synthesis in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Pooled it
- Predictive biomarkers of biologic therapy response in chronic rhinosinusitis with nasal polyps: a systematic review.Frontiers in medicine · 2026Pooled it
- Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).International forum of allergy & rhinology · 2026Trial
- Rethinking Monospecific Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps: Dual- and Multispecific Antibodies.Clinical reviews in allergy & immunology · 2026Review
- Comparison of two classification systems for tissue eosinophilia in patients with chronic rhinosinusitis with nasal polyps.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Estimation of the indirect costs associated with chronic rhinosinusitis with nasal polyposis in Spain: an analysis from a societal perspective.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Observational
- Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?International forum of allergy & rhinology · 2026Review
- Socioeconomic and regional influences on eosinophilic inflammation in chronic rhinosinusitis with nasal polyps.The World Allergy Organization journal · 2026Article
- Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.International forum of allergy & rhinology · 2026Article
- The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge.Journal of clinical medicine · 2026Review
- Tezepelumab in Chronic Rhinosinusitis with Nasal Polyps: Pathophysiology, Clinical Evidence, and Therapeutic Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Heterogeneity and clinical relevance of group 2 innate lymphoid cells subsets in nasal polyps.The Journal of allergy and clinical immunology · 2026Article
- Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) with Mepolizumab or Dupilumab: A Preliminary Single-Center Study for Evaluation of Safety and Efficacy.Journal of personalized medicine · 2026Article
- Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study.Journal of clinical medicine · 2026Article
- Chronic Respiratory Diseases: The Stories You Don't Want to Miss.Medicina (Kaunas, Lithuania) · 2026Article
- Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications-An EAACI Task Force Report.Allergy · 2026Article
- Understanding Biologics in CRSwNP: Related Events and Insights.Current allergy and asthma reports · 2026Review
- Modifying the course of asthma: mechanisms and strategies for clinical remission.Current opinion in allergy and clinical immunology · 2026Review
- [Indications of biological treatment in patients with chronic rhinosinusitis with nasal polyps].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-world studies (RWSs). This systematic review and meta-analysis aimed to summarise the efficacy and safety of these four biologics in real-world settings. Primary outcomes were nasal polyp score and sino-nasal outcome test-22 score. Secondary outcomes included smell identification test score, loss of smell score, nasal congestion score, overall nasal symptom score, treatment response, and adverse events (AEs) prompting discontinuation. Efficacy outcomes at 4, 6, 12, and over 12 months were summarised, and meta-analyses of mean changes from baseline were conducted. Sixty-four RWSs involving 3921 patients were included. Significant improvements in clinical outcomes were observed at most follow-up time points, with dupilumab showing particularly notable effects. The efficacy observed in these RWSs was superior to that demonstrated in phase 3 RCTs. All biologics exhibited low discontinuation rates due to AEs. Overall, biologic treatments for CRSwNP in real-world settings demonstrate strong efficacy and good safety. However, the limitations in current RWSs highlight the need for long-term, high-quality multicentre prospective studies and comprehensive healthcare database analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.